Nifty
Sensex
:
:
13817.55
46874.36
-149.95 (-1.07%)
-535.57 (-1.13%)

Pharmaceuticals & Drugs - Global

Rating :
51/99  (View)

BSE: 500124 | NSE: DRREDDY

4871.80
-37.50 (-0.76%)
28-Jan-2021 | 4:05PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  4845.00
  •  4903.95
  •  4777.00
  •  4909.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1033094
  •  50330.27
  •  5512.65
  •  2495.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 81,633.25
  • 50.74
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 83,645.63
  • 0.51%
  • 4.90

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.73%
  • 5.42%
  • 7.81%
  • FII
  • DII
  • Others
  • 29.13%
  • 14.28%
  • 16.63%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.86
  • 2.39
  • 7.05

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.70
  • -7.18
  • 0.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.03
  • -1.34
  • 29.25

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.74
  • 32.55
  • 30.79

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.41
  • 3.71
  • 3.56

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.73
  • 17.81
  • 17.70

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
4,910.90
4,812.80
2.04%
4,426.50
3,858.20
14.73%
4,448.90
4,029.60
10.41%
4,397.10
3,864.60
13.78%
Expenses
3,754.80
3,749.00
0.15%
3,305.20
3,116.50
6.05%
3,499.70
3,210.70
9.00%
4,685.80
3,060.00
53.13%
EBITDA
1,156.10
1,063.80
8.68%
1,121.30
741.70
51.18%
949.20
818.90
15.91%
-288.70
804.60
-
EBIDTM
23.54%
22.10%
25.33%
19.22%
21.34%
20.32%
-6.57%
20.82%
Other Income
51.20
54.00
-5.19%
87.10
430.10
-79.75%
73.60
83.30
-11.64%
67.30
102.30
-34.21%
Interest
25.20
30.30
-16.83%
23.30
29.80
-21.81%
23.00
24.50
-6.12%
15.20
24.10
-36.93%
Depreciation
316.50
313.10
1.09%
292.30
289.00
1.14%
274.10
287.20
-4.56%
286.90
290.30
-1.17%
PBT
865.60
774.40
11.78%
892.80
853.00
4.67%
725.70
590.50
22.90%
-523.50
592.50
-
Tax
101.10
-320.70
-
305.90
192.80
58.66%
-44.90
150.80
-
32.50
101.10
-67.85%
PAT
764.50
1,095.10
-30.19%
586.90
660.20
-11.10%
770.60
439.70
75.26%
-556.00
491.40
-
PATM
15.57%
22.75%
13.26%
17.11%
17.32%
10.91%
-12.64%
12.72%
EPS
46.44
66.59
-30.26%
35.78
40.70
-12.09%
47.00
27.43
71.35%
-32.39
30.14
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
18,183.40
17,517.00
15,448.20
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
Net Sales Growth
9.77%
13.39%
8.17%
0.60%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
 
Cost Of Goods Sold
5,846.10
5,554.40
4,494.80
4,039.50
3,696.50
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
Gross Profit
12,337.30
11,962.60
10,953.40
10,241.50
10,499.60
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
GP Margin
67.85%
68.29%
70.90%
71.71%
73.96%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
Total Expenditure
15,245.50
15,046.60
12,270.00
11,929.80
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
Power & Fuel Cost
-
314.80
329.10
329.30
330.10
315.20
339.10
319.90
335.40
225.90
183.30
% Of Sales
-
1.80%
2.13%
2.31%
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
Employee Cost
-
3,380.20
3,356.20
3,214.90
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
% Of Sales
-
19.30%
21.73%
22.51%
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
Manufacturing Exp.
-
1,445.40
1,434.80
1,746.50
1,886.60
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
% Of Sales
-
8.25%
9.29%
12.23%
13.29%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
General & Admin Exp.
-
1,195.20
1,132.10
1,193.40
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
% Of Sales
-
6.82%
7.33%
8.36%
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
Selling & Distn. Exp.
-
1,408.30
1,423.50
1,330.20
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
% Of Sales
-
8.04%
9.21%
9.31%
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
Miscellaneous Exp.
-
1,748.30
99.50
76.00
70.60
483.00
65.70
35.60
38.50
85.20
744.90
% Of Sales
-
9.98%
0.64%
0.53%
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
EBITDA
2,937.90
2,470.40
3,178.20
2,351.20
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
EBITDA Margin
16.16%
14.10%
20.57%
16.46%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
Other Income
279.20
620.60
337.50
155.20
171.50
295.00
274.10
169.90
149.90
132.30
52.30
Interest
86.70
98.30
88.90
78.80
63.40
82.60
108.20
126.70
100.30
114.10
32.30
Depreciation
1,169.80
1,163.10
1,134.80
1,077.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
PBT
1,960.60
1,829.60
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
Tax
394.60
-140.30
385.80
438.00
296.50
751.10
563.20
683.10
637.90
503.50
183.90
Tax Rate
20.13%
-7.67%
16.83%
32.43%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
PAT
1,566.00
1,969.90
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
PAT before Minority Interest
1,566.00
1,969.90
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
8.61%
11.25%
12.34%
6.39%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
PAT Growth
-41.71%
3.34%
108.92%
-27.43%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
 
Unadjusted EPS
94.17
118.45
114.62
54.86
75.60
126.74
140.49
118.05
91.81
78.23
60.07

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
15,598.80
14,023.60
12,571.60
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
Share Capital
83.10
83.00
83.00
82.90
85.30
85.20
85.10
84.90
84.80
84.60
Total Reserves
15,411.90
13,861.10
12,406.00
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
Non-Current Liabilities
-807.50
2,113.00
2,538.40
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
Secured Loans
130.40
55.20
63.00
59.70
74.70
77.50
94.70
80.20
26.10
24.40
Unsecured Loans
0.00
2,144.80
2,445.90
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
Long Term Provisions
74.50
79.30
81.70
84.20
95.20
77.90
56.30
51.40
33.30
28.80
Current Liabilities
7,214.10
5,897.30
6,893.80
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
Trade Payables
1,524.80
1,367.10
1,334.50
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
Other Current Liabilities
3,512.00
2,820.70
2,411.40
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
Short Term Borrowings
1,653.20
1,212.50
2,556.20
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
Short Term Provisions
524.10
497.00
591.70
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
Total Liabilities
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
Net Block
6,850.30
7,191.00
6,968.00
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
Gross Block
19,335.50
18,048.40
17,436.30
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
Accumulated Depreciation
12,146.40
10,857.40
10,468.30
9,001.70
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
Non Current Assets
9,406.30
10,923.80
11,505.40
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
Capital Work in Progress
1,535.10
2,933.50
3,470.50
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
Non Current Investment
309.10
334.20
465.30
682.60
329.70
145.60
0.40
0.40
0.90
0.90
Long Term Loans & Adv.
688.70
426.70
564.80
482.10
290.40
418.10
232.20
149.10
70.10
64.10
Other Non Current Assets
23.10
38.40
36.80
34.50
44.30
6.40
0.00
20.90
0.00
0.00
Current Assets
12,599.10
11,110.10
10,498.40
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
Current Investments
2,368.70
2,252.90
1,833.00
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
Inventories
3,506.70
3,357.90
2,908.90
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
Sundry Debtors
5,027.80
3,986.90
4,052.70
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
Cash & Bank
205.30
222.80
263.80
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
Other Current Assets
1,490.60
849.80
765.90
451.50
1,115.60
1,231.00
1,214.60
961.90
705.80
879.60
Short Term Loans & Adv.
444.50
439.80
674.10
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
Net Current Assets
5,385.00
5,212.80
3,604.60
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
Total Assets
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
2,984.10
2,870.40
1,803.00
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
PBT
1,885.70
2,335.80
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
Adjustment
2,562.50
835.00
1,625.30
1,687.30
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
Changes in Working Capital
-753.60
183.70
-896.60
-519.60
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
Cash after chg. in Working capital
3,694.60
3,354.50
2,079.10
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-710.50
-484.10
-276.10
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-492.30
-772.70
-1,488.30
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
Net Fixed Assets
-453.50
-275.60
-683.20
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
Net Investments
-1,552.00
-297.00
-534.60
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
Others
1,513.20
-200.10
-270.50
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
Cash from Financing Activity
-2,515.90
-2,132.60
-444.00
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
Net Cash Inflow / Outflow
-24.10
-34.90
-129.30
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
Opening Cash & Equivalents
222.80
254.20
377.80
492.10
539.50
862.40
520.40
736.20
573.00
660.00
Closing Cash & Equivalent
196.20
222.80
254.20
377.80
492.10
582.90
862.40
520.40
736.20
575.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
932.31
840.01
752.35
734.72
731.49
572.92
457.33
371.04
290.91
235.90
ROA
8.95%
8.66%
4.23%
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
ROE
13.38%
14.42%
7.40%
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
ROCE
10.81%
13.41%
8.21%
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
Fixed Asset Turnover
0.94
0.87
0.86
0.92
1.13
1.23
1.23
1.26
1.17
1.04
Receivable days
93.92
94.98
100.33
101.86
96.43
89.72
87.97
87.19
79.59
70.77
Inventory Days
71.52
74.03
73.63
69.56
60.11
60.27
62.06
62.74
65.60
71.20
Payable days
39.56
39.46
37.10
31.00
28.67
28.48
33.96
34.99
35.37
72.19
Cash Conversion Cycle
125.88
129.55
136.86
140.42
127.87
121.51
116.06
114.93
109.82
69.78
Total Debt/Equity
0.14
0.28
0.41
0.40
0.27
0.44
0.58
0.58
0.66
0.59
Interest Cover
19.61
26.78
18.14
25.51
35.61
27.80
21.89
22.58
16.81
37.62

News Update


  • Dr. Reddy's Laboratories gets nod to conduct phase 3 clinical trial for Sputnik V vaccine in India
    16th Jan 2021, 09:25 AM

    The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, doubleblind, parallel-group, placebo-controlled study in India

    Read More
  • Dr. Reddy’s Laboratories gets approval for phase 3 trials of Sputnik V Covid-19 vaccine
    12th Jan 2021, 10:35 AM

    DSMB’s clearance is based on the safety data from the phase 2 clinical trial

    Read More
  • Dr. Reddy's Laboratories launches Febuxostat Tablets in US Market
    11th Jan 2021, 14:54 PM

    The company's Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets

    Read More
  • Dr. Reddy's, RDIF commence clinical trials for Sputnik V vaccine in India
    2nd Dec 2020, 09:16 AM

    This will be a multicenter and randomized controlled study, which will include safety and immunogenicity study

    Read More
  • Dr. Reddy’s enters into definitive agreement with Glenmark Pharmaceuticals
    30th Nov 2020, 08:40 AM

    The agreement aims to acquire brands Momat Rino, Momat Rino Advance, Momat A, Glenspray and Glenspray Active

    Read More
  • Dr. Reddy’s launches Succinylcholine Chloride Injection in US Market
    13th Nov 2020, 08:53 AM

    The company's Succinylcholine Chloride Injection USP, 200 mg/10 mL is available in multi-dose vials

    Read More
  • Dr. Reddy's partners with BIRAC for Sputnik V vaccine clinical trials in India
    29th Oct 2020, 12:55 PM

    The partnership will allow Dr. Reddy’s to identify and use some of BIRAC’s clinical trial centres for the vaccine

    Read More
  • Dr. Reddy's Laboratories reports 30% fall in Q2 consolidated net profit
    28th Oct 2020, 16:03 PM

    Total income of the company increased by 1.96% at Rs 4962.10 crore for Q2FY21

    Read More
  • Dr. Reddys Lab - Quarterly Results
    28th Oct 2020, 13:23 PM

    Read More
  • Dr. Reddy's Laboratories isolates all data centre services due to cyber-attack
    22nd Oct 2020, 12:53 PM

    In the wake of a detected cyber-attack, the company has isolated all data centre services to take required preventive actions

    Read More
  • Dr. Reddy’s re-launches over-the-counter Famotidine Tablets
    20th Oct 2020, 12:47 PM

    The company’s OTC Famotidine Tablets USP, 10 mg and 20 mg, are available in multiple pack sizes to allow consumers a variety of purchasing options

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.